CS02 Changes the Landscape of Diabetes Treatment: CenterLab Announces Positive Topline Results of Phase 2 Trial

TAIPEI, July 10, 2020 /PRNewswire/ -- Center Laboratories Inc. (CenterLab: 4123.TWO), a pharmaceutical company dedicated in specialty drug product development, announced today that the anti-diabetic drug – CS02 meets its primary endpoint. The topline results of a phase 2 clinical trial of CS02...